Percutaneous Transvenous Balloon Mitral Commissurotomy: A Single-Center Experience

Authors

Ashraf Ahmed, Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.Follow
Nazar Mohammed, Department of Interventional Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Alaa Rahhal, Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Hakam Abdallah Alzaeem, Department of Non-Invasive Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Cheikh Abdoul Maaly, Department of General Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Tariq Mousa, Department of Interventional Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Shabib Al Asmi, Department of General Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Basel Bitar, Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
Fahad Al-Kindi, Department of Interventional Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Salaheddin Omran Arafa, Department of Interventional Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Awad Al-Qahtani, Department of Interventional Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Mohammed Al-Hijji, Department of Interventional Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.

Document Type

Article

Publication Title

Heart views : the official journal of the Gulf Heart Association

Abstract

BACKGROUND: Rheumatic heart disease and its impact on cardiac health is still a concern in developing countries. Percutaneous trans-mitral commissurotomy (PTMC) is the standard of care in managing severe rheumatic mitral stenosis (MS). This article reports a single-center, 10-year real-world experience in Qatar. METHODS: In this retrospective study, we reviewed all the patients who underwent PTMC in Qatar between January 1, 2012, and January 1, 2022. Periprocedural data were collected at baseline, postprocedural, 1 year, and during the last follow-up. The primary outcome was procedural success (improvement in valve area by 50%, final valve area >1.5 cm, and freedom from > moderate mitral regurgitation, stroke, or pericardial effusion). Safety endpoints were freedom from death, periprocedural cardiogenic shock and cardiac arrest, stroke urgent mitral valve replacement (MVR), or pericardiocentesis. Long-term outcomes included the requirement of redo PTMC or MVR, in addition to rehospitalization due to arrhythmias, heart failure, or stroke. RESULTS: Sixty-five patients were included in the review (age 42 ± 10, female 38 [58.5%]). Sixty-two patients (95.4%) had a successful procedure. One patient developed a hemorrhagic pericardial tamponade and cardiogenic shock, for which he underwent pericardiocentesis and emergency aortic root repair. One patient developed acute stroke 8 h after the procedure, and one patient had tamponade resolved with emergency pericardiocentesis. Two patients required MVR after 1 and 4 years, respectively. CONCLUSION: PTMC is the mainstay of rheumatic MS management in patients with suitable anatomy as most patients have excellent outcomes with long-term freedom from surgery, which has been the case in our single-center experience.

First Page

127

Last Page

132

DOI

10.4103/heartviews.heartviews_78_22

Publication Date

1-1-2022

Recommended Citation

Ahmed, Ashraf; Mohammed, Nazar; Rahhal, Alaa; Alzaeem, Hakam Abdallah; Maaly, Cheikh Abdoul; Mousa, Tariq; Al Asmi, Shabib; Bitar, Basel; Al-Kindi, Fahad; Arafa, Salaheddin Omran; Al-Qahtani, Awad; and Al-Hijji, Mohammed, "Percutaneous Transvenous Balloon Mitral Commissurotomy: A Single-Center Experience" (2022). Internal Medicine. 280.
https://scholar.bridgeporthospital.org/internal_medicine/280

Identifier

36479163 (pubmed); PMC9721178 (pmc); 10.4103/heartviews.heartviews_78_22 (doi); HV-23-127 (pii)